Press Releases


Latest News


Adamas Announces Positive Results from its Phase 2 Proof-of-Concept Study of ADS-5102 for the Treatment of Walking Impairment in Multiple Sclerosis (MS) Patients
Jun 13, 2016 | General Releases

Adamas Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) at the 20th International Congress of Parkinson's and Movement Disorders
May 16, 2016 | General Releases

Adamas Reports First Quarter 2016 Financial Results
May 10, 2016 | Financial Releases

Adamas Announces New Employment Inducement Grant
May 6, 2016 | General Releases

Adamas Announces Positive Top-line Results from its Phase 3 EASE LID 3 Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients with Parkinson's Disease
Apr 28, 2016 | General Releases

Adamas to Host Conference Call and Webcast to Provide Company Update
Apr 28, 2016 | General Releases

Adamas Presents Positive Findings From the Phase 3 EASE LID Clinical Trial of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) Associated with Parkinson's Disease at the American Academy of Neurology Annual Meeting
Apr 20, 2016 | General Releases

Adamas Announces Data Update at the 68th American Academy of Neurology Annual Meeting
Apr 14, 2016 | General Releases

Adamas Reports Fourth Quarter and Full Year 2015 Financial Results
Feb 23, 2016 | Financial Releases

Adamas Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
Feb 22, 2016 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11 12